These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 24769332)

  • 1. AXT914 a novel, orally-active parathyroid hormone-releasing drug in two early studies of healthy volunteers and postmenopausal women.
    John MR; Harfst E; Loeffler J; Belleli R; Mason J; Bruin GJ; Seuwen K; Klickstein LB; Mindeholm L; Widler L; Kneissel M
    Bone; 2014 Jul; 64():204-10. PubMed ID: 24769332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans.
    John MR; Widler L; Gamse R; Buhl T; Seuwen K; Breitenstein W; Bruin GJ; Belleli R; Klickstein LB; Kneissel M
    Bone; 2011 Aug; 49(2):233-41. PubMed ID: 21514409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH(2)] in postmenopausal women with osteoporosis.
    Henriksen K; Andersen JR; Riis BJ; Mehta N; Tavakkol R; Alexandersen P; Byrjalsen I; Valter I; Nedergaard BS; Teglbjaerg CS; Stern W; Sturmer A; Mitta S; Nino AJ; Fitzpatrick LA; Christiansen C; Karsdal MA
    Bone; 2013 Mar; 53(1):160-6. PubMed ID: 23234813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral daily PTH(1-34) tablets (EB613) in postmenopausal women with low BMD or osteoporosis: a randomized, placebo-controlled, 6-month, phase 2 study.
    Tripto-Shkolnik L; Szalat A; Tsvetov G; Rouach V; Sternberg C; Hoppe A; Burshtein G; Galitzer H; Toledano M; Harari G; Santora AC; Cosman F
    J Bone Miner Res; 2024 Jul; 39(6):672-682. PubMed ID: 38578978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women.
    Hämmerle SP; Mindeholm L; Launonen A; Kiese B; Loeffler R; Harfst E; Azria M; Arnold M; John MR
    Bone; 2012 Apr; 50(4):965-73. PubMed ID: 22289659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A New Therapeutic Approach Using a Calcilytic (AXT914) for Postsurgical Hypoparathyroidism in Female Rats.
    Lim YS; You BH; Kim HB; Lim SH; Song JG; Bae MG; Han HK; Choi YH; Choi HS
    Endocrinology; 2020 Oct; 161(10):. PubMed ID: 32852547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-dose subcutaneous administration of recombinant human parathyroid hormone [rhPTH(1-84)] in healthy postmenopausal volunteers.
    Schwietert HR; Groen EW; Sollie FA; Jonkman JH
    Clin Pharmacol Ther; 1997 Mar; 61(3):360-76. PubMed ID: 9084461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of oral recombinant human parathyroid hormone [rhPTH(1-31)NH₂] in postmenopausal women with osteoporosis.
    Sturmer A; Mehta N; Giacchi J; Cagatay T; Tavakkol R; Mitta S; Fitzpatrick L; Wald J; Trang J; Stern W
    Clin Pharmacokinet; 2013 Nov; 52(11):995-1004. PubMed ID: 23719683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the effect of chronic administration of a calcium-sensing receptor antagonist, ronacaleret, on renal calcium excretion and serum calcium in postmenopausal women.
    Caltabiano S; Dollery CT; Hossain M; Kurtinecz MT; Desjardins JP; Favus MJ; Kumar R; Fitzpatrick LA
    Bone; 2013 Sep; 56(1):154-62. PubMed ID: 23756230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation.
    Kumar S; Matheny CJ; Hoffman SJ; Marquis RW; Schultz M; Liang X; Vasko JA; Stroup GB; Vaden VR; Haley H; Fox J; DelMar EG; Nemeth EF; Lago AM; Callahan JF; Bhatnagar P; Huffman WF; Gowen M; Yi B; Danoff TM; Fitzpatrick LA
    Bone; 2010 Feb; 46(2):534-42. PubMed ID: 19786130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1-Alkyl-4-phenyl-6-alkoxy-1H-quinazolin-2-ones: a novel series of potent calcium-sensing receptor antagonists.
    Widler L; Altmann E; Beerli R; Breitenstein W; Bouhelal R; Buhl T; Gamse R; Gerspacher M; Halleux C; John MR; Lehmann H; Kalb O; Kneissel M; Missbach M; Müller IR; Reidemeister S; Renaud J; Taillardat A; Tommasi R; Weiler S; Wolf RM; Seuwen K
    J Med Chem; 2010 Mar; 53(5):2250-63. PubMed ID: 20158186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of growth hormone administration on bone mineral metabolism, PTH sensitivity and PTH secretory rhythm in postmenopausal women with established osteoporosis.
    Joseph F; Ahmad AM; Ul-Haq M; Durham BH; Whittingham P; Fraser WD; Vora JP
    J Bone Miner Res; 2008 May; 23(5):721-9. PubMed ID: 18052753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mixed-effects modeling of the pharmacodynamic response to the calcimimetic agent R-568.
    Lalonde RL; Gaudreault J; Karhu DA; Marriott TB
    Clin Pharmacol Ther; 1999 Jan; 65(1):40-9. PubMed ID: 9951429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JTT-305, an orally active calcium-sensing receptor antagonist, stimulates transient parathyroid hormone release and bone formation in ovariectomized rats.
    Kimura S; Nakagawa T; Matsuo Y; Ishida Y; Okamoto Y; Hayashi M
    Eur J Pharmacol; 2011 Oct; 668(1-2):331-6. PubMed ID: 21810422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy.
    Greenspan SL; Holland S; Maitland-Ramsey L; Poku M; Freeman A; Yuan W; Kher U; Gertz B
    Proc Assoc Am Physicians; 1996 May; 108(3):230-8. PubMed ID: 8774056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
    J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An acute intake of phosphate increases parathyroid hormone secretion and inhibits bone formation in young women.
    Kärkkäinen M; Lamberg-Allardt C
    J Bone Miner Res; 1996 Dec; 11(12):1905-12. PubMed ID: 8970892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1-34, parathyroid hormone-related protein 1-36, and SDZ-parathyroid hormone 893.
    Stewart AF; Cain RL; Burr DB; Jacob D; Turner CH; Hock JM
    J Bone Miner Res; 2000 Aug; 15(8):1517-25. PubMed ID: 10934650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.